Clinicopathologic features and outcome after liver resection for hepatocellular carcinoma in patients with concurrent versus previous chronic hepatitis B

Surgery Today

Volumn 35, Issue 3, 2005, Pages 216-222

  Kubo, Shoji ^a   Tanaka, Hiromu ^a   Shuto, Taichi ^a   Takemura, Shigekazu ^a   Yamamoto, Takatsugu ^a   Kanazawa, Akishige ^a   Uenishi, Takahiro ^a   Tanaka, Shogo ^a   Hirohashi, Kazuhiro ^a   Nishiguchi, Shuhei ^a   Kinoshita, Hiroaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alcohol abuse; Diabetes mellitus; Hepatitis B virus; Hepatocellular carcinoma; Liver resection

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHRONIC HEPATITIS; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PORTAL VEIN; POSTOPERATIVE PERIOD; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SURGICAL ANATOMY; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR VOLUME;

AGE DISTRIBUTION; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COMORBIDITY; FEMALE; HEPATECTOMY; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; JAPAN; LIVER NEOPLASMS; MALE; POSTOPERATIVE COMPLICATIONS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20144389066     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00595-004-2919-x     Document Type: Article

References (37)

1. Sherlock S, Dooley J. Diseases of the liver and biliary system. 10th ed. Oxford: Blackwell Science; 1997.
2. Ohba K, Kubo S, Tamori A, Hirohashi K, Tanaka H, Shuto T, et al. Previous or occult infection with hepatitis B virus in hepatitis B surface antigen-negative and anti-hepatitis C negative patients with hepatocellular carcinoma. Surg Today 2004;34:842-8.
3. Yano Y, Yamashita F, Sumie S, Ando E, Fukumori K, Kiyama M, et al. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gastroenterol 2002;97:156-61.
4. Shuto T, Hirohashi K, Kubo S, Tanaka H, Tsukamoto T, Yamamoto T, et al. Changes and results of surgical strategies for hepatocellular carcinoma: results of a 15-year study on 452 consecutive patients. Surg Today 1998;28:1124-9.
5. Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathological features and results of surgical treatment. Ann Surg 1990;211:277-87.
6. Minamitani S, Nishiguchi S, Kuroki T, Otani S, Monna T. Detection by ligase chain reaction of precore mutant of hepatitis B virus. Hepatology 1997;25:216-22.
7. Edmondson HA, Steiner PE. Primary carcinoma of the live: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
8. Liver Cancer Study Group of Japan: Classification of primary liver cancer. 1st English ed. Tokyo: Kanehara; 1997.
9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
10. Tamori A, Nishiguchi S, Kubo S, Koh N, Moriyama Y, Fujimoto S, et al. Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus. Hepatology 1999;29:1429-34.
11. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001;34:194-203.
12. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001;34:204-6.
13. Tamori A, Nishiguchi S, Kubo S, Enomoto M, Koh N, Takeda T, et al. Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol 2003;69:475-81.
14. Tamori A, Nishiguchi S, Kubo T, Narimatsu D, Habu T, Takeda K, et al. HBV DNA integration and HBV-transcript expression in non-B non-C hepatocellular carcinoma in Japan. J Med Virol 2003;71:492-8.
15. Kubo S, Nishiguchi S, Tamori A, Hirohashi K, Kinoshita H, Kuroki T. Development of hepatocellular carcinoma in patients with HCV infection, with or without past HBV infection, and relationship to age at the time of transfusion. Vox Sang 1998;74:129.
16. Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Kuorki T, Minamitani S, et al. Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis. Jpn J Cancer Res 1998;89:419-26.
17. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999;86:793-8.
18. Kubo S, Tamori A, Ohba K, Shuto T, Yamamoto T, Tanaka H, et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci 2001;46:2408-14.
19. Kojima M, Udo K, Takahashi Y, Yoshizawa H, Tsuda F, Itoh Y, et al. Correlation between titer of antibody to hepatitis B core antigen and presence of viral antigens in the liver. Gastroenterology 1977;73:644-7.
20. Omata M, Afroudakis A, Liew CT, Ashcavai M, Peter RL. Comparison of serum hepatitis B surface antigen (HBsAg) and serum anticore with tissue HBsAg and hepatitis B core antigen (HBcAg). Gastroenterology 1978;75:1003-9.
21. Blum HE, Liang TJ, Galun E, Wands JR. Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection. Hepatology 1991;14:56-62.
22. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992;103:1649-56.
23. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993;18:1313-8.
24. Kato J, Hasegawa K, Torii N, Yamauchi K, Hayashi N. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology 1996;23:389-95.
25. Rehermann B, Darrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.
26. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;93:230-9.
27. Yu MC, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991;83:1820-6.
28. Kuper H, Ye W, Broomé U, Romelsjö A, Mucci LA, Ekbom A, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism or cirrhosis. Hepatology 2001;34:714-8.
29. Eguchi H, Umesaka K, Sakon M, Nagano H, Ito Y, Kishimoto A, et al. Presence of active hepatitis associated with liver cirrhosis is a risk factor for mortality caused by posthepatectomy liver failure. Dig Dis Sci 2000;45:1383-8.
30. Kubo S, Tsukamoto T, Hirohashi K, Tanaka H, Shuto T, Takemura S, et al. Correlation between preoperative serum concentration of type IV collagen 7s domain and hepatic failure following resection of hepatocellular carcinoma. Ann Surg 2004;239:186-93.
31. Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamazaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg 1986;10:844-50.
32. Tanaka H, Kinoshita H, Hirohashi K, Kubo S, Lee KC. Increased safety by two-stage hepatectomy with preoperative portal vein embolization in rats. J Surg Res 1994;57:687-92.
33. Kubo S, Kinoshita H, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, et al. The efficacy of preoperative portal vein embolization prior o a major hepatectomy for patients with an impaired liver function: a retrospective study. J Hepatobiliary Pancreat Surg 1997;4:359-64.
34. Tanaka H, Hirohashi K, Kubo S, Shuto T, Higaki I, Kinoshita H. Preoperative portal vein embolization improves prognosis after right lobectomy for hepatocellular carcinoma in patients with impaired hepatic function. Br J Surg 2000;87:879-82.
35. Tanaka H, Hirohashi K, Kubo S, Ikebe T, Tsukamoto T, Hamba H, et al. Influence of histological inflammatory activity on regenerative capacity of liver after percutaneous transhepatic portal vein embolization. J Gastroenterol 1999;34:100-4.
36. Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Yamamoto T, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000;88:1016-24.
37. Kubo S, Hirohashi K, Yamazaki O, Matsuyama M, Tanaka H, Horii K, et al. Effect of presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg 2001;26:555-60.